Peijia Medical (HKG:9996) forecasts its 2024 revenue to surge by 38% to 43% year-over-year to between 610 million yuan and 630 million yuan.
The surge is attributable to growth in the medical equipment company's neuro-interventional product lines and a greater share in the Chinese transcatheter aortic valve replacement market, according to a Monday filing with the Hong Kong Exchange.